acquired
Stage
1
Investors
About
Dice Therapeutics is a clinical-stage biotechnology company developing medicines in immunology (and oncology). The company went public in 2021 as NASDAQ:DICE and was later acquired by Eli Lilly for $2.4B.
Explore Dice Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.